The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 30, 2024

Filed:

Sep. 25, 2018
Applicants:

Jsr Corporation, Minato-ku, JP;

Jsr Life Sciences Corporation, Minato-ku, JP;

Jsr Life Sciences, Llc, Sunnyvale, CA (US);

Jsr Micro N.v., Leuven, BE;

Inventors:

Jun-ichi Yasuoka, Minato-ku, JP;

Kiichi Yoshimura, Minato-ku, JP;

Tomoaki Haga, Minato-ku, JP;

Assignees:

JSR CORPORATION, Minato-ku, JP;

JSR Life Sciences Corporation, Minato-ku, JP;

JSR Life Sciences, LLC, Sunnyvale, CA (US);

JSR Micro N.V., Leuven, BE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/195 (2006.01); C07K 1/22 (2006.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); B01D 15/38 (2006.01); B01J 20/00 (2006.01); B01J 20/30 (2006.01); B01J 20/24 (2006.01); B01J 20/288 (2006.01); G01N 33/543 (2006.01);
U.S. Cl.
CPC ...
C07K 14/195 (2013.01); B01D 15/3809 (2013.01); B01J 20/24 (2013.01); B01J 20/288 (2013.01); B01J 20/3085 (2013.01); C07K 1/22 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); G01N 33/54366 (2013.01); B01J 2220/52 (2013.01);
Abstract

Provided are a protein L-derived immunoglobulin binding protein having an increased antibody dissociation rate under acidic conditions, and an affinity support using the same. Disclosed are an immunoglobulin binding protein comprising at least one mutant of an immunoglobulin binding domain, and an affinity support comprising a solid-phase support having the immunoglobulin binding protein bound thereto. A mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 85% with the sequence set forth in any one of SEQ ID NO:1 to SEQ ID NO:9 and a predetermined mutation, and the mutant has immunoglobulin κ chain binding activity.


Find Patent Forward Citations

Loading…